The GOG Highlight Reel – January 2025

Activity Overview

The GOG Foundation, Inc. and GOG Partners are thrilled to present the “The GOG Highlight Reel”, an ongoing Education Series that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year. A twice-yearly event, our most recent program took place Saturday, January 18, 2025, in Phoenix, Arizona alongside the 2025 NRG Oncology Winter Meeting.

The GOG Highlight reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course takes a deep dive into clinical trials for gynecologic malignancies, offering insights on recent data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians to comprehend the evolving treatment landscape, including understanding available trials in progress. Participants will receive a synthesis of recent studies and explore key components of clinical trials, gaining essential knowledge for research in these malignancies. Dynamic discussions analyze emerging approved therapies and investigational agents, providing insights into current (as well as future) advancements. Join us for a journey through clinical trials in ovarian, endometrial and cervical cancers, gaining the analytical skills to navigate the latest oncology research and clinical care confidently.

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: AbbVie, Acrivon Therapeutics, AstraZeneca, Corcept Therapeutics, GSK, and Eisai.

The GOG Foundation, Inc., would also like to thank our sponsors for this symposium: Pfizer/Genmab and GSK.

Target Audience

The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate:

Increased knowledge regarding:

• • The current agents and regimens used in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers.
  • The key trial data for newer therapies in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers.
  • The current investigational agents and regimens under evaluation for the treatment of advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers.

Greater competence related to:

• • Understanding the available and selecting therapies and treatments for women with cervical, endometrial, and ovarian cancers.
  • Interpret and understand the application of recent data into clinical practice.
  • Learn about current clinical trials in gynecologic cancers and understand what opportunities exist in the public domain.